MedTrace Logo

Hysteroscopic Injections of Autologous Endometrial Cells and Platelet-rich Plasma in Patients With Thin Endometrium

NCT05455151 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2022-07-13

No results posted yet for this study

Summary

The investigation is devoted to the study of the effect of the introduction of autologous platelet-rich plasma (PRP) on the thickness of the endometrium. It was found that the injection of PRP and endometrial cells resuspended in PRP into the endometrium of patients with thin endometrium leads to an increase in the proliferation of endometrial cells, and as a result, to an increase in its thickness.

Conditions

  • Thin Endometrium

Interventions

PROCEDURE

Conservative therapy

Conservative therapy to which the patients were subjected was the effect of an electrical impulse

BIOLOGICAL

PRP injection

This intervention consisted of injecting platelet-rich plasma (PRP) into the endometrium

BIOLOGICAL

Injection of PRP after conservative therapy

This intervention consisted of conducting conservative therapy with an electrical impulse and then injecting PRP inside the endometrium

BIOLOGICAL

Injection of PRP with endometrial cells

This intervention consisted of injecting endometrial cells suspended in prp

Sponsors & Collaborators

  • Sechenov University

    collaborator OTHER

  • Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare

    lead OTHER_GOV

Principal Investigators

  • Inna Apolikhina, MD · FSBI "National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov" Ministry of Healthcare of the Russian Federation

  • Zulfiia Efendieva, PhD · FSBI "National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov" Ministry of Healthcare of the Russian Federation

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2021-01-11
Completion
2021-03-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05455151 on ClinicalTrials.gov